Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Adamas Pharmaceuticals Inc.
Headquarters: Emeryville, CA, United States of America
Website: N/A
Year Founded: 2000
Status: Acquired
BioCentury | Oct 10, 2023
Management Tracks
Amgen veteran Lenz named head of R&D at Neumora
Plus: Eaton leaving Editas as CTO, CBO and updates from Poseida, Zevra, Pheon, Lexicon and more
BioCentury | Jun 13, 2023
Management Tracks
Patni becomes chief of R&D at Reata
Plus: Reilly named CEO at Damona, and updates from Akebia, Generate, Jasper and more
BioCentury | Sep 29, 2022
Management Tracks
Kevin Bunker promoted to CSO at Zentalis
Plus Fonck becomes partner at Pureos, and updates from 4D Molecular, Gandeeva, Code and more
BioCentury | Sep 21, 2022
Management Tracks
New CEOs at Scholar Rock, Neuway, NeuVasQ and ProLynx
Plus Serono’s Maria Rivas joins Pfizer, and updates from
BioCentury | Aug 4, 2022
Management Tracks
Sanofi’s Lih-Ling Lin joins PharmaEssentia as CSO
Plus Hunder becomes CMO at ProfoundBio, and updates from Nurix, Sanofi and Nucleai
BioCentury | Apr 20, 2022
Management Tracks
New CEOs at eGenesis, Fore and Cerevance
Plus Ramanan joins Turnstone as CFO, updates from Camp4, ImmPact, Akoya and more
BioCentury | Oct 12, 2021
Product Development
Oct. 11 Quick Takes: Supernus diversifies CNS portfolio with Adamas acquisition
Plus: Idorsia’s miss, Evotec, Protagonist, Enzyvant and Chance
BioCentury | Feb 2, 2021
Product Development
Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas
Immunovant Inc. (NASDAQ:IMVT) lost 42% to $25.08 on Tuesday after announcing it was pausing trials of anti-FCRN mAb IMVT-1401 (batoclimab) due to elevated total cholesterol and LDL signals in the
BioCentury | Jan 8, 2020
Company News
Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone
BioCentury | Apr 6, 2018
Finance
Smid-cap smorgasbord
Buysiders like 2Q cancer catalysts, rare diseases and small- to mid-cap milestones
Items per page:
1 - 10 of 65